Simultaneous Integrated Boost Radiotherapy in Unresectable Stage IV (M0) Head and Neck Squamous Cell Cancer Patients: Daily Clinical Practice

• Published in: Reports of practical oncology and radiotherapy 2020-05, Vol.25 (3), p.399-404
• Main Authors: Iatì, Giuseppe, Parisi, Silvana, Santacaterina, Anna, Pontoriero, Antonio, Cacciola, Alberto, Brogna, Anna, Platania, Angelo, Palazzolo, Carmela, Cambareri, Domenico, Davì, Valerio, Napoli, Ilenia, Lillo, Sara, Severo, Cesare, Tamburella, Consuelo, Vadalà, Roberta, Delia, Pietro, Pergolizzi, Stefano
• Format: Article
• Language: English
• Subjects: Head and neck cancer; Intensity-Modulated radiotherapy (IMRT); Original research article; Radiotherapy; Simultaneous integrated boost (SIB); Systemic therapies
• ISSN: 1507-1367; 2083-4640
• DOI: 10.1016/j.rpor.2020.04.006

To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice. Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies. We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated. 37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months. SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.